Frequency of New Onset Diabetes Mellitus in Patients Receiving Treatment for Diffuse Large B Cell Lymphoma

Abstract

Objectives: To determine the frequency of new-onset diabetes mellitus in patients receiving treatment for diffuse large B-cell lymphoma. Methodology: This study was done at Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore after Six months following approval of the study synopsis from 7^th February to 7^th May. We enrolled 150 patients aged 18–40 years with newly diagnosed DLBCL were enrolled using non-probability consecutive sampling. Patients with prior diabetes or central nervous system lymphoma were excluded. Glycemic status was assessed post-chemotherapy using fasting blood glucose and HbA1c. Associations with demographic and clinical variables were analyzed. Results: New-onset diabetes mellitus was observed in 32.0% (n = 48) of patients. A significant association was found with family history of diabetes (p = 0.009) whereas age, BMI, gender, smoking, alcohol use, lymphoma stage, or type of therapy had no significant association. Conclusion: The frequency of new-onset diabetes among DLBCL patients undergoing chemotherapy is substantial. Family history of diabetes emerged as a significant risk factor. Routine screening for hyperglycemia should be incorporated into oncology care to ensure early diagnosis and management of diabetes during cancer treatment.